First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Ph 1/2/3 Clinical Study for Natrunix™ Therapy for Colorectal Cancer
- Investigators are combining XBiotech’s Natrunix with trifluridine/tipiracil as a new candidate therapy for metastatic colorectal cancer.
- Subjects receiving the experimental therapy have failed earlier treatment with oxaliplatin, irinotecan, and fluoropyrimidine.
- Subjects are randomized to receive Natrunix plus trifluridine/tipiracil chemotherapy or placebo plus the chemotherapy.
- The study is designed to seamlessly proceed through Phase III development based on achievement of certain efficacy milestones in the Phase I/II portions.
Share:
More News
Elevation Oncology today announced that it has entered into a definitive merger agreement with Concentra Biosciences, LLC, whereby Concentra will acquire Elevation Oncology for $0.36 in cash per share of Elevation Oncology common stock, plus one non-tradeable contingent value right, which represents the right to receive: (i) 100% of the
“The AMPLITUDE study reinforces the power of a biomarker-driven approach and the potential of this novel combination regimen to shift the treatment paradigm in prostate cancer,” said Henar Hevia, Ph.D., Senior Director, EMEA Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine. “By identifying patients most likely to benefit from
“We are gaining significant momentum on CHM CDH17 and look forward to our interactions with the FDA to get our advanced therapy to patients in need”, said Dr Rebecca McQualter CEO of Chimeric.
“Bringing VVD-214, the only clinical-stage covalent inhibitor of WRN in development worldwide, into our portfolio marks an incredibly exciting moment for Vividion,” said Aleksandra Rizo, M.D., Ph.D., Chief Executive Officer of Vividion. “We are eager to progress development of this compound, building on the encouraging clinical data we’ve seen to
